| Prev Close | 27.02 |
| Open | 27.00 |
| Day Low/High | 26.46 / 27.02 |
| 52 Wk Low/High | 23.90 / 76.98 |
| Volume | 234.09K |
Esperion Therapeutics, Inc. (ESPR)
26.89
0.13
0.48
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 27.94B |
| Market Cap | 755.57M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
3 Small Biotechs With Potential Catalysts at Hand
Esperion Therapeutics, Agenus Inc. and Baudax Bio could see coming events trigger positive reactions in their shares.
Watch These Biotech Names on Strong Earnings
Merger activity is the number 1 driver I am watching for biotech growth.
Frustration Levels Are High, but This Is Constructive Market Action
Strong markets tend to stay sticky to the upside, and the mild pressure on the indices isn't preventing some good stock picking.
IBM's Pricey Red Hat Deal Helps Put Pep in Market's Step
There is much talk that IBM is overpaying for Red Hat, but this deal is a net positive for the market as a whole.
Biotechs Remain the Best Place For Stock Picking
Biotech companies show more energy than the rest of the market Monday.
It's Time to Bring the Heat
I'm starting a new periodic feature that will bring you the hottest-trading stocks I see.
Better Breadth, But a Tired Close
Buyers were hesitant to keep pressing as the day wrapped up.
Bulls Steadfast, but Market Players Skittish
Not a big day of gains, but there is underlying support.
Market Has a Mood Swing to the Upside
Gloom is gone as likelihood of Fed rate hike fades.
Flow of Bad News Pours Over Market
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
Troubled Stocks Go From Worst to First
Oil- and commodity-related shares perform well.
Where the Money Was Made the Last 5 Years
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
A Down Day, But No Cause for Alarm
Thin volume likely ahead of holiday weekend.
This Isn't What This Market Needs
A flood of supply in a nervous market isn't a good idea.
Backing Away From Biotechs
This sector could see some real damage.
Biotech Stocks at a Crossroad
Own them, or take something off the table?
These Stocks Get Benefit of the Doubt
Market backtracks on skepticism over biotechs.
Looking Back to Go Forward
For Bluebird Bio and Esperion, the charts tell the whole story.
Remarkable Biotech Runs Continue
A Fed-related dip may be your only hope to get in lower.
What Is Wrong With You People?
These companies are doing great -- take some profits!
How I Deal with Gap-Up Trades
A tale of two stocks with Esperion and DSW.
Momentum Is Not Dead
The chasing in certain areas was intense.
Damage to Indices Was Fairly Minimal
But stay disciplined, honor your stops and protect gains.
NanoString Best BioTech IPO
Three biotech companies are going public this week and NanoString looks better than Prosensa or Esperion says Francis Gaskins.
